Zobrazeno 1 - 5
of 5
pro vyhledávání: '"M A, Macham"'
Autor:
P Beale, M A Macham, Julieann Sludden, A Rodriguez, J.S. de Bono, C Hutchison, N M Bleehen, Chris Twelves, I Dennis, C Gardner, P Vasey, A Flavin, Ian Judson
Publikováno v:
British Journal of Cancer. 80:1786-1791
Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::030db030eeeb143a49293b0753865ed8
https://doi.org/10.1038/sj.bjc.6690598
https://doi.org/10.1038/sj.bjc.6690598
Autor:
M A Macham, M. Soukop, Donald Bissett, R C Leonard, James Paul, Gordon C. Wishart, A. N. Harnett, David J. Kerr, Duncan I. Jodrell, T. Habeshaw
Publikováno v:
Journal of Clinical Oncology. 12:1771-1777
PURPOSE To evaluate the effect of quinidine, a putative modulator of P-glycoprotein-mediated drug resistance, on the response rate and toxicity profile of epirubicin in patients with advanced breast cancer. PATIENTS AND METHODS Between 1989 and 1992,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e307a3cf1c9a860c65c7eb11d743e3c1
https://doi.org/10.1200/jco.1994.12.9.1771
https://doi.org/10.1200/jco.1994.12.9.1771
Publikováno v:
British Journal of Cancer
Nitrosoureas are the drugs most effective in the treatment of patients with intracerebral malignant glioma. Their limiting toxicity is delayed myelosuppression. A prospective, randomised crossover study of recombinant human granulocyte-macrophage col
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c892404e34ef6a15b93a9a4ebb6aded
http://europepmc.org/articles/PMC1968853
http://europepmc.org/articles/PMC1968853
Autor:
M Uzzel, M A Macham, S Campbell, S M Bailey, R Glasspool, H. J. Mackay, Mark A. Hill, C Martin, David Cunningham, Timothy J. Price, Chris Twelves, A. Massey
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 14(8)
Background: The aim of this study was to determine the maximum tolerated dose (MTD), toxicity profile and response rate of the oral 5-fluorouracil prodrug UFT (tegafur/uracil) and leucovorin (LV) in combination with irinotecan in patients with advanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1919118db64feec24c2b508b0abb3343
https://pubmed.ncbi.nlm.nih.gov/12881390
https://pubmed.ncbi.nlm.nih.gov/12881390
Autor:
C J, Twelves, C, Gardner, A, Flavin, J, Sludden, I, Dennis, J, de Bono, P, Beale, P, Vasey, C, Hutchison, M A, Macham, A, Rodriguez, I, Judson, N M, Bleehen
Publikováno v:
British Journal of Cancer
DACA, also known as XR5000, is an acridine derivative active against both topoisomerase I and II. In this phase I study, DACA was given as a 3-h intravenous infusion on 3 successive days, repeated every 3 weeks. A total of 41 patients were treated at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3964f5042c44c7c3ad104a82a8cc7bfd
https://pubmed.ncbi.nlm.nih.gov/10468297
https://pubmed.ncbi.nlm.nih.gov/10468297